D-0343-2026 Class III Ongoing

Recalled by Slate Run Pharmaceuticals — Columbus, OH

FDA drug recall D-0343-2026 was initiated by Slate Run Pharmaceuticals on Feb 12, 2026 and is designated Class III. Reason for recall: Labeling: Not Elsewhere Classified. The carton for Eptifibatide Injection 75 mg/100 mL states 75 mg/100 mL vial for weight-adjusted bolus dosing. The approved statement is 75 mg/100 mL vial for… The recall status is ongoing.

Recall details

Product Type
Drugs
Report Date
Mar 4, 2026
Initiation Date
Feb 12, 2026
Voluntary/Mandated
Voluntary: Firm initiated

Product description

Eptifibatide Injection, 75 mg/100 mL vial for weight-adjusted bolus dosing, 1x100 mL Single-dose Vial, For Intravenous Use Only, Rx Only, Manufactured by: Hainan Poly Pharm. Co., Ltd., Guilinyang Economic Development Area, Haikou, Hainan Province, China 571127; Distributed by: Slate Run Pharmaceuticals, LLC, Columbus, Ohio 43215. NDC Slate Run Carton Label: 70436-027-80; NDC ProRx Carton Label: 70436-163-80

Reason for recall

Labeling: Not Elsewhere Classified. The carton for Eptifibatide Injection 75 mg/100 mL states 75 mg/100 mL vial for weight-adjusted bolus dosing. The approved statement is 75 mg/100 mL vial for weight-adjusted infusion.

Distribution pattern

Nationwide within the USA.

Code information

All lots within expiry

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0343-2026
openFDA file date
Nov 10, 2026
Loaded by RegDataLab
Nov 11, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0343-2026. Report a data issue: hello@regdatalab.com.